Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2017 | Novel issues in the combined modality treatment of lymphomas

Lena Specht, MD, DMSc, from the University of Copenhagen, Copenhagen, Denmark, discusses an overview of the workshop she chaired, ‘Novel issues in the combined modality treatment of lymphomas’, at the International Conference on Malignant Lymphoma (ICML) 2017 in Lugano, Switzerland. Currently, radiotherapy is the most effective way of increasing the antigenicity of tumours. Experiments with animals have shown that checkpoint inhibitors, combined with radiotherapy, is now being tested in clinical trials, but the results have not yet been released. NK/T-cell lymphoma, more common in Asia, as it tends to be multi-drug resistant, are treated with L-asparaginase chemotherapy and high-dose radiation.